Cargando…

Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes

AIM: To investigate the use of thermosensitive magnetoliposomes (TMs) loaded with magnetic iron oxide (Fe(3)O(4)) and the anti-cancer stem cell marker CD90 (CD90@TMs) to target and kill CD90(+) liver cancer stem cells (LCSCs). METHODS: The hepatocellular carcinoma cell line Huh7 was used to separate...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Rui, An, Li Y., Miao, Qin F., Li, Feng M., Han, Yong, Wang, Hui X., Liu, Dang P., Chen, Rong, Tang, Sha Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094971/
https://www.ncbi.nlm.nih.gov/pubmed/27145285
http://dx.doi.org/10.18632/oncotarget.9116
Descripción
Sumario:AIM: To investigate the use of thermosensitive magnetoliposomes (TMs) loaded with magnetic iron oxide (Fe(3)O(4)) and the anti-cancer stem cell marker CD90 (CD90@TMs) to target and kill CD90(+) liver cancer stem cells (LCSCs). METHODS: The hepatocellular carcinoma cell line Huh7 was used to separate CD90(+) LCSCs by magnetic-activated cell sorting. CD90@TMs was characterized and their ability to target CD90(+) LCSCs was determined. Experiments were used to investigate whether CD90@TMs combined with magnetic hyperthermia could effectively eliminate CD90(+) LCSCs. RESULTS: The present study demonstrated that CD90(+) LCSCs with stem cells properties were successfully isolated. We also successfully prepared CD90@TMs that was almost spherical and uniform with an average diameter of 130±4.6 nm and determined that magnetic iron oxide could be incorporated and retained a superparamagnetic response. CD90@TMs showed good targeting and increased inhibition of CD90(+) LCSCs in vitro and in vivo compared to TMs. CONCLUSION: CD90@TMs can be used for controlled and targeted delivery of anticancer drugs, which may offer a promising alternative for HCC therapy.